Hubbry Logo
Mediator (coactivator)Mediator (coactivator)Main
Open search
Mediator (coactivator)
Community hub
Mediator (coactivator)
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Mediator (coactivator)
Mediator (coactivator)
Mediator (coactivator)
View on Wikipedia
from Wikipedia

Figure 1: Diagram of Mediator with its cyclin-dependent kinase module attached

Mediator is a multiprotein complex that functions as a transcriptional coactivator in all eukaryotes. It was discovered in 1990 in the lab of Roger D. Kornberg, recipient of the 2006 Nobel Prize in Chemistry.[1][2] Mediator[a] interacts with transcription factors and RNA polymerase II. It mainly functions to transmit signals from the transcription factors to the polymerase.[3]

Mediator complexes are variable at the evolutionary, compositional and conformational levels.[3] Figure 1 shows only one "snapshot" of what a particular complex might comprise,[b] but it is an inaccurate depiction of the conformation in vivo. During evolution, Mediator has complexified. The yeast Saccharomyces cerevisiae (a simple eukaryote) is thought to have up to 21 subunits in the core Mediator (exclusive of the CDK module), while mammals have up to 26.

Individual subunits can be absent or replaced by other subunits under different conditions. Also, there are many intrinsically disordered regions in Mediator proteins, which may contribute to the conformational flexibility seen both with and without other bound proteins or protein complexes. A more realistic model of Mediator without the CDK module is shown in Figure 2.[4]

Mediator is required for successful transcription of genes by RNA polymerase II, and contacts the polymerase in the transcription preinitiation complex.[3] A recent model showing the polymerase associating with Mediator without DNA is shown in Figure 3.[4] In addition to RNA polymerase II, Mediator must also associate with transcription factors and DNA; a model of such interactions is shown in Figure 4.[5] Note that the different morphologies of Mediator do not necessarily mean that a particular model is correct; rather those differences may reflect the flexibility of Mediator as it interacts with other molecules.[c] For example, after binding the enhancer and core promoter, the Mediator complex compositionally changes, dissociating the kinase module and associating with RNA polymerase II for transcriptional activation.[6]

Mediator is located within the cell nucleus. It is required for successfully transcribing nearly all class II gene promoters in yeast.[7] It works similarly in mammals. Mediator functions as a coactivator and binds to the C-terminal domain of RNA polymerase II holoenzyme, bridging this enzyme and transcription factors.[8]

Structure

[edit]
Figure 5: Mediator complex architecture with focus on the disordered "spline" of MED14[9]

The yeast Mediator complex is approximately as massive as a small subunit of a eukaryotic ribosome. The yeast Mediator has 25 subunits, while the mammalian Mediator is slightly larger.[3] Mediator comprises 4 main parts: the head, middle, tail, and the transiently associated CDK8 kinase module.[10]

Mediator subunits have many intrinsically disordered regions called "splines", which may be important to allow the structural changes of Mediator that change the function of the complex.[3][d] Figure 5 shows the splines of the MED14 subunit connecting a large portion of the complex together while still allowing flexibility.[4][e]

Mediator complexes lacking a subunit have been found or produced. These smaller complexes can still function normally in some activity, but lack other capabilities.[3] This indicates a somewhat independent function of some of the subunits while composing the larger complex.

Another example of structural variability is seen in vertebrates, in which 3 paralogues of subunits of the cyclin-dependent kinase (CDK) module have evolved by 3 independent gene duplication events followed by sequence divergence.[3]

Figure 2: Mediator structural model[9]

There is a report that Mediator stably associates with a particular type of non-coding RNA, ncRNA-a.[11][f] These stable associations regulate gene expression in vivo, and are prevented by mutations in MED12 that produce the human disease FG syndrome.[11] Thus, the structure of a Mediator complex can be augmented by RNA as well as proteinaceous transcription factors.[3]

Function

[edit]
Figure 3: Structural model of Mediator's tail and middle bound to RNA polymerase II[9]

Mediator was originally discovered because it was important for RNA polymerase II function, but it has many more functions than just interactions at the transcription start site.[3]

RNA polymerase II–Mediator core initiation complex

[edit]
Figure 4: Model of Mediator with some transcription factors, Pol II and DNA

Mediator is a crucial component for transcription initiation. Mediator interacts with the pre-initiation complex, composed of RNA Polymerase II and general transcription factors TFIIB, TFIID, TFIIE, TFIIF, and TFIIH to stabilize and initiate transcription.[12] Studies of Mediator–RNA Pol II contacts in budding yeast showed the importance of TFIIB-Mediator contacts in the formation of the complex. Interactions of Mediator with TFIID in the initiation complex has been shown.[10]

The structure of a core Mediator (cMed) while associated with a core pre-initiation complex was elucidated.[12]

RNA synthesis

[edit]

The preinitiation complex, which contains Mediator, transcription factors, a nucleosome[13][14][g] and RNA polymerase II, is important for positioning the polymerase for the start of transcription. Before RNA synthesis starts, the polymerase dissociates from Mediator. This is seemingly via phosphorylation of the polymerase by a kinase. Importantly, Mediator and transcription factors do not dissociate from the DNA when the polymerase begins transcription. Rather, the complex remains at the promoter to recruit another RNA polymerase to begin another round of transcription.[3][h]

There is some evidence to suggest that Mediator in Schizosaccharomyces pombe helps regulate RNA polymerase III (Pol III) transcripts of tRNAs.[15] An independent report confirmed Mediator specifically associating with Pol III in Saccharomyces cerevisiae.[16] Those authors also reported specific associations with RNA polymerase I and proteins involved in transcription elongation and RNA processing, supporting other evidence of Mediator's involvement in elongation and processing.[16]

Chromatin organization

[edit]

Mediator is involved in chromatin looping, which brings distant regions of a chromosome into closer physical proximity.[3] The ncRNA-a mentioned above[11] is involved in such looping.[i] Enhancer RNAs (eRNAs) can function similarly.[3]

In addition to euchromatin looping, Mediator helps form or maintain heterochromatin at centromeres and telomeres.[3]

Signal transduction

[edit]

TGFβ signaling at the cell membrane involves two different intracellular pathways. Only one depends on MED15.[j][17] In both human cells and Caenorhabditis elegans, MED15 helps lipid homeostasis through the SREBP-containing pathway.[18] In the model plant Arabidopsis thaliana, the ortholog of MED15 is required for signaling by the plant hormone salicylic acid,[19] while MED25 is required for the transcriptional activation of responses to hypoxia, jasmonate and shade signalling.[20][21][22][23] Two components of the CDK module (MED12 and MED13) are involved in the Wnt signaling pathway.[3] MED23 is involved in the RAS/MAPK/ERK pathway.[3] This abbreviated review shows the versatility of individual Mediator subunits, and leads to the idea that Mediator is an end-point of signaling pathways.[3]

Human disease

[edit]

Involvement of Mediator in various human diseases has been reviewed.[24][25][26][27][28][29][30][31][32][33][34][excessive citations] Since inhibiting one interaction of a disease-causing signaling pathway with a subunit of Mediator may not inhibit general transcription needed for normal function, Mediator subunits are attractive candidates for therapeutic drugs.[3]

Interactions

[edit]
Mediator interactome in Saccharomyces cerevisiae[16]

Very gentle cell lysis in yeast followed by co-immunoprecipitation with an antibody to a MED17 has confirmed almost all previously reported or predicted interactions and revealed many previously unsuspected specific interactions of various proteins with Mediator.[16]

MED1

[edit]
Main article: MED1
The interaction network of MED1 protein from BioPlex 2.0

Details of the first subunit are illustrative of the types of information that may be gathered for other subunits. See § Subunit composition for them.

Regulation by MicroRNAs

[edit]

MicroRNAs help regulate the expression of many proteins. MED1 is targeted by miR-1, which is important in gene regulation in cancers.[35] The tumor suppressor miR-137 also regulates MED1.[36]

Mouse embryonic development

[edit]

Null mutants die early (embryonic day 11.5).[37][38] Investigating hypomorphic mutants (which survive 2 days longer) found that placental defects were primarily lethal and that there were also defects in cardiac and hepatic development, but many other organs were normal.[38]

Mouse cells and tissues

[edit]
A Mediator mutation causes hairy teeth in mice

In mice, conditional mutations can be produced to affect only specific cells or tissues at specific times, so that the mouse can develop to adulthood to have its adult phenotype studied. In one case, MED1 was found to participate in controlling the timing of events of meiosis in male mice.[39] Conditional mutants in keratinocytes differ in skin wound healing.[40] A conditional mutation in mice changed dental epithelium into epidermal epithelium, which caused hair to grow beside the incisors.[41]

Subunit composition

[edit]

The Mediator complex is composed of at least 31 subunits in all eukaryotes studied: MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED28, MED29, MED30, MED31, CCNC, and CDK8. There are three fungal-specific components, referred to as MED2, MED3 and MED5.[42]

The subunits form at least three structurally distinct submodules. The head and the middle modules interact directly with RNA polymerase II, whereas the elongated tail module interacts with gene-specific regulatory proteins. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation.

  • The head module contains: MED6, MED8, MED11, SRB4/MED17, SRB5/MED18, ROX3/MED19, SRB2/MED20 and SRB6/MED22.
  • The middle module contains: MED1, MED4, NUT1/MED5, MED7, CSE2/MED9, NUT2/MED10, SRB7/MED21 and SOH1/MED31. CSE2/MED9 interacts directly with MED4.
  • The tail module contains: MED2, PGD1/MED3, RGR1/MED14, GAL11/MED15 and SIN4/MED16.
  • The CDK8 module contains: MED12, MED13, CCNC and CDK8. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP.

In other species

[edit]

Below is a cross-species comparison of Mediator complex subunits.[42][43]

Subunit No. Human gene C. elegans gene D. melanogaster gene S. cerevisiae gene Sch. pombe gene
MED1 MED1 Sop3/mdt-1.1, 1.2 MED1 MED1 med1
MED2[k] MED2
MED3[k] PGD1
MED4 MED4 MED4 MED4 med4
MED5[k] NUT1
MED6 MED6 MDT-6 MED6 MED6 med6
MED7 MED7 MDT-7/let-49 MED7 MED7 med7
MED8 MED8 MDT-8 MED8 MED8 med8
MED9 MED9 MED9 CSE2
MED10 MED10 MDT-10 NUT2 med10
MED11 MED11 MDT-11 MED11 MED11 med11
MED12 MED12 MDT-12/dpy-22 MED12 SRB8 srb8
MED12L MED12L
MED13 MED13 MDT-13/let-19 MED13 SSN2 srb9
MED14 MED14 MDT-14/rgr-1 MED14 RGR1 med14
MED15 MED15 mdt-15 MED15 GAL11 YN91_SCHPO[l]
MED16 MED16 MED16 SIN4
MED17 MED17 MDT-17 MED17 SRB4 med17
MED18 MED18 MDT-18 MED18 SRB5 med18
MED19 MED19 MDT-19 MED19 ROX3[42] med19
MED20 MED20 MDT-20 MED20 SRB2 med20
MED21 MED21 MDT-21 MED21 SRB7 med21
MED22 MED22 MDT-22 MED22 SRB6 med22
MED23 MED23 MDT-23/sur-2 MED23
MED24 MED24 MED24
MED25 MED25 MED25
MED26 MED26 MED26
MED27 MED27 MED27 med27
MED28 MED28 MED28
MED29 MED29 MDT-19 MED29
MED30 MED30 MED30
MED31 MED31 MDT-31 MED31 SOH1 med31
CCNC CCNC cic-1 CycC SSN8 pch1
CDK8 CDK8 cdk-8 Cdk8 SSN3 srb10

Notes

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Mediator (coactivator)

View on Grokipedia
from Grokipedia
The complex is a large, multi-subunit coactivator essential for regulating transcription by (Pol II) in eukaryotes, acting as a bridge between gene-specific transcription factors bound to enhancers and the basal transcription machinery at promoters. Conserved from to humans, it consists of approximately 26 subunits in mammals forming a 1.4 MDa structure organized into modular head, middle, and tail domains, with an optional reversible kinase module comprising CDK8, cyclin C, MED12, and MED13. First identified in the through studies in and mammalian systems, the complex integrates activating signals to facilitate Pol II recruitment, preinitiation complex assembly, and transcriptional initiation while also influencing elongation and enhancer-promoter looping. Key subunits such as MED1 interact with nuclear receptors and other activators, MED14 serves as a structural backbone connecting modules, and MED26 recruits elongation factors, enabling context-specific . The tail module primarily contacts transcription factors, the head module binds Pol II, and the middle module coordinates overall architecture, with conformational flexibility allowing dynamic responses to cellular signals. Dysregulation of Mediator has been implicated in diseases including cancer, underscoring its role as a central hub in transcriptional control.

Structure and Composition

Overall Architecture

The Mediator complex is a multisubunit transcriptional coactivator essential for eukaryotic , comprising 25–30 subunits in humans and exhibiting evolutionary conservation across eukaryotes, with at least 22 core subunits shared from yeast to mammals. The complex is organized into a core (cMED) module, consisting of head, middle, and tail submodules, alongside a dissociable CDK8 kinase module (CKM) that includes subunits MED12, MED13, cyclin C (CCNC), and CDK8. The human cMED has an estimated mass of approximately 1 MDa, forming a large macromolecular assembly that bridges transcription factors and . Recent cryo-EM structures from 2020–2024 have elucidated the 's modular architecture and conformational dynamics, revealing both compact and extended states that regulate its interactions. For instance, the 2021 structure of Mediator at 3.5 Å resolution shows a tail-extended conformation (MED^E) and a tail-bent form (MED^B), with the head and middle modules maintaining a conserved sandwich-like organization. A 2024 study further resolved the complete cMED-CKM complex at 4.7 Å for cMED and 6.7 Å for CKM, demonstrating how CKM binding to the cMED "hook" via intrinsically disordered regions (IDRs) of MED12 and MED13 induces a compact conformation (~460 Å × 210 Å × 160 Å overall), while dissociation yields an extended state that exposes binding sites for RNA Pol II and MED26. This CKM regulation sterically hinders Pol II docking in the compact form, modulating 's coactivator activity through conformational switching. Beyond rigid structures, participates in biomolecular to form dynamic transcriptional hubs, as revealed by 2021 studies on its liquid-liquid (LLPS) properties. IDRs in subunits such as MED1, MED15, MED25, and MED26 drive multivalent weak interactions that promote LLPS, concentrating , transcription factors, and RNA Pol II into nuclear condensates (~300 nm in diameter) at active gene loci, including super-enhancers. These condensates facilitate enhancer-promoter clustering and transcriptional bursting by enhancing reinitiation efficiency, with of the RNA Pol II CTD (e.g., Ser5 by CDK7) disrupting LLPS to transition condensates toward elongation phases.

Modules and Subunits

The Mediator coactivator complex in humans consists of approximately 26 subunits organized into four main modules: the head, middle, tail, and -dependent kinase 8 (CDK8) kinase module (CKM). The head module comprises 10-12 subunits, including MED6, MED8, MED11, MED17, MED18, MED20, MED22, MED26, MED27, MED28, MED29, and MED30, which primarily interact with (Pol II). The middle module includes 7-9 subunits such as MED1, MED4, MED7, MED9, MED10, MED19, and MED21, serving as a structural scaffold that links other modules. The tail module contains 7-9 subunits, notably MED2, MED3, MED5, MED14, MED15, MED16, MED23, MED24, and MED25, which facilitate recruitment by transcription factors. The CKM, a dissociable submodule, is composed of four subunits: MED12 (or its paralog MED12L), MED13 (or MED13L), CDK8 (or CDK19), and C (CCNC), which modulates the core complex's activity. Subunit composition varies across species, reflecting evolutionary adaptations. In the yeast Saccharomyces cerevisiae, the Mediator complex has 21 subunits, lacking several metazoan-specific ones like MED23, MED25, MED26, MED28, and MED30 found in humans. This results in a smaller complex size of about 0.9 MDa in yeast compared to 1.4 MDa in humans, with conserved core functions but expanded regulatory diversity in higher eukaryotes. Assembly of complex follows a hierarchical process, with the module initiating to promoter-bound activators, followed by integration of the head and middle modules via scaffolding by MED14. The CKM docks reversibly to specific sites on the head-middle interface, often displacing MED26 to repress transcription initiation. This modular assembly allows dynamic reconfiguration during transcription. Post-translational modifications, particularly , influence Mediator composition by altering subunit stability and module interactions. For instance, phosphorylation of MED1 at sites T1032 and T1457 by ERK enhances its integration into the middle module and complex stability. Similarly, phosphorylation of MED15 in the tail module suppresses non-stress changes, while MED13 phosphorylation and ubiquitination regulate CKM docking and dissociation. These modifications ensure context-specific assembly without permanently altering subunit counts. Recent cryo-EM structures from 2024 reveal detailed subunit interactions in the human core (cMED) and CKM, showing CKM binding via MED12 and MED13 to a "hook" region on cMED, with MED13's intrinsically disordered region (IDR) occluding Pol II and MED26 binding sites to enforce repression. These insights, at resolutions of 4.7 Å for cMED and 6.7 Å for the full complex, highlight conserved mechanisms across species and underscore the role of IDRs in modular flexibility.

Functions in Transcription

Initiation Complex Formation

The Mediator complex serves as a critical bridge between gene-specific transcription factors and the basal transcription machinery, including (Pol II) and general transcription factors such as TFIID and TFIIH, to facilitate the assembly of the pre-initiation complex (PIC) at eukaryotic promoters. Recruited by transcription factors bound to enhancer or promoter elements, Mediator coordinates the recruitment and stabilization of Pol II and associated factors, ensuring precise positioning for transcription start site selection. This bridging function is essential for integrating regulatory signals into the core transcriptional apparatus, promoting cooperative PIC formation without directly contacting DNA. Central to PIC assembly is the formation of the RNA Pol II–Mediator core initiation complex, where Mediator directly interacts with the C-terminal domain (CTD) of Pol II's largest subunit, RPB1. Structural studies reveal multiple CTD binding sites on : in , the CTD spans 11 heptapeptide repeats that bridge the head and middle modules via interactions with subunits like Med6, Med31, and Med4, stabilizing the complex and priming it for initiation. In humans, the CTD docks at sites between the head-middle modules and near CDK7 of TFIIH, positioning it for , which is a key regulatory step in PIC maturation. These interactions enhance Pol II recruitment to promoters, forming a holoenzyme-like scaffold that integrates with TFIIB, TFIIF, and other PIC components. Upon binding transcription factors, Mediator undergoes significant conformational changes, notably displacement and of the tail module, which exposes Pol II docking sites and facilitates PIC assembly. Cryo-EM structures show that transcription factor engagement with tail subunits (e.g., MED15, MED1) induces a ~40° of the relative to the core, coupled with movements in the hook region (Med10, Med14) and widening of the CTD-binding cleft. These dynamics, observed in mammalian and fungal systems, transition from a closed, inactive state to an open configuration that accommodates Pol II and general factors. Recent studies from 2020–2023 elucidate the detailed docking mechanism of Mediator-Pol II, highlighting allosteric rearrangements that stabilize the core initiation complex. High-resolution cryo-EM of human Mediator-bound PIC reveals flexible tethering of transcription factor sites in the tail, allowing modular assembly while CDK7 contacts stabilize the CTD for Ser5 phosphorylation, essential for promoter clearance. In yeast, the addition of nucleosome-like elements further refines CTD-Mediator interfaces, bridging modules to enhance complex stability prior to open complex formation. These findings underscore a stepwise docking process where tail displacement precedes core-Pol II engagement, ensuring regulatory control. The energy landscape of complex formation, without involvement of elongation factors, is characterized by 's shape-shifting conformational ensembles that lower barriers for Pol II recruitment and PIC stabilization. binding to the tail or middle modules shifts the free energy landscape, increasing the population of open states conducive to CTD docking and general factor integration, as evidenced by allosteric models of dynamics. This flexible landscape enables rapid, gene-specific transitions to productive , with structural plasticity preventing premature elongation commitment.

Elongation and RNA Synthesis

Following the transition from transcription initiation, the complex plays a critical role in stabilizing the elongating form of () and facilitating productive RNA synthesis. interacts directly with Pol II to form stable clusters that associate with , promoting the progression of Pol II through the early elongation phase. These interactions help maintain Pol II processivity by counteracting pausing and enhancing the recruitment of key s, such as positive transcription elongation factor b (P-TEFb). For instance, the module (MKM), comprising CDK8 or CDK19 and associated subunits like MED12, recruits P-TEFb to phosphorylate the C-terminal domain (CTD) of Pol II at serine 2, which is essential for releasing Pol II from promoter-proximal pauses and enabling efficient elongation. Mediator modulates promoter-proximal pausing of Pol II, a regulatory checkpoint where Pol II halts shortly after initiation to allow coordination of . The MKM within promotes pause release by phosphorylating components of the negative elongation factor (NELF) complex, displacing it from Pol II and allowing the transition to productive elongation. Additionally, subunits like MED26 serve as docking sites for such as the little elongation complex (LEC), which further supports pause release at specific gene classes, including those involved in rapid transcriptional responses. Depletion of MED12, for example, reduces P-TEFb occupancy at gene bodies, leading to increased pausing and decreased elongation rates, as observed in studies of interferon-γ-induced genes. These mechanisms ensure that not only stabilizes elongating Pol II but also fine-tunes the timing of synthesis to match cellular needs. Mediator integrates with super-enhancers to drive high-level transcription during elongation, where dense clusters of enhancers recruit to concentrate Pol II and coactivators in phase-separated condensates. These condensates enhance Pol II processivity and RNA output by increasing local concentrations of elongation machinery, particularly at genes defining cell identity. ChIP-seq analyses reveal that occupancy is markedly elevated at super-enhancers—often 10- to 100-fold higher than at typical enhancers—directly correlating with enhanced transcription rates and Pol II density in gene bodies. For example, in embryonic stem cells, super-enhancer-associated clusters sustain high elongation speeds, with occupancy levels predicting up to 50% of variance in mRNA production rates across the genome. Recent 2022 reviews highlight these dynamics, emphasizing 's role in bridging super-enhancer signals to elongation control without disrupting the core initiation complex.

Termination and Processing

The Mediator complex plays a in facilitating the termination of (Pol II) transcription and the subsequent processing of mRNA 3' ends, ensuring precise boundaries. In , the Mediator subunit Srb5/Med18 (also known as Med18) is essential for recruiting cleavage and factors to gene terminators, promoting efficient Pol II release. Specifically, Srb5/Med18 cross-links to both promoter and terminator regions of activated genes like INO1 and CHA1, and its absence impairs the recruitment of CF1 complex components such as Rna15 (a functional analog of Pcf11) and CPF subunit Pta1 to 3' ends, leading to Pol II accumulation and read-through transcription beyond poly(A) signals. This association underscores Mediator's involvement in linking termination factor assembly to Pol II dissociation, with Srb5/Med18 potentially aiding in gene looping that transfers Pol II from terminators back to promoters. In human cells, recent structural and functional studies have elucidated 's direct crosstalk with the cleavage and polyadenylation specificity factor (CPSF) complex, which is pivotal for mRNA 3' end cleavage and . associates with CPSF through the interaction between its subunit MED23 and CPSF component FIP1, with MED23 functioning as an that directly engages 3' mRNAs at both promoter-proximal and terminator regions. This binding facilitates CPSF recruitment to nascent transcripts, coordinating cleavage site recognition and poly(A) tail addition. Disruption of the MED23-FIP1 interface, such as through MED23 depletion or overexpression of FIP1's intrinsically disordered regions, reduces CPSF occupancy at terminators, thereby compromising Pol II release and triggering widespread transcriptional . The dissociation of from the transcription elongation complex appears tightly coupled to 3' processing events, where MED23's RNA-binding activity senses poly(A) signals, promoting Mediator reconfiguration and handover to termination machinery for Pol II disengagement. Cryo-electron microscopy and functional assays from 2023-2025 reveal that this dynamic involves modular rearrangements in the human core, particularly in the tail module housing MED23, enabling sequential interactions that prevent aberrant elongation. Such mechanisms enhance fidelity by minimizing read-through transcription, which can generate aberrant fusion transcripts and increase complexity, as observed in hundreds of events upon MED23 loss in models. Overall, these findings highlight Mediator's evolutionarily conserved yet human-specific adaptations in termination, distinct from its roles in elongation.

Roles in Chromatin and Gene Regulation

Chromatin Remodeling

The Mediator complex plays a pivotal role in by serving as a scaffold that recruits histone acetyltransferases (HATs) such as p300 and CBP, often through its MED1 subunit, to promoter regions. This recruitment facilitates local acetylation, which loosens structure and enhances accessibility for transcriptional machinery. For instance, MED1 interacts directly with nuclear receptors and coactivators to bridge HATs to the Mediator core, promoting the formation of a complex that acetylates and alters nucleosome positioning. In addition, Mediator associates with ATP-dependent remodelers like the complex (known as RSC in yeast), enabling cooperative eviction of nucleosomes and maintenance of open states at promoters. These interactions ensure that repressive chromatin barriers are dismantled prior to transcription . Mediator contributes to nucleosome displacement specifically at promoter-proximal regions, where it helps establish and maintain -depleted regions (NDRs). By binding directly to via subunits such as MED19 and MED26, Mediator stabilizes the preinitiation complex (PIC) in proximity to the +1 , the first nucleosome downstream of the transcription start site (TSS). This positioning facilitates partial displacement or repositioning of the +1 , reducing its occupancy and allowing to access the promoter DNA. Structural studies reveal that Mediator-PIC contacts the +1 at positions approximately 40-50 base pairs downstream of the TSS, enhancing transcriptional output without fully evicting the , thus integrating dynamics with initiation. In models, Mediator's interaction with RSC promotes the eviction of within NDRs, preventing their reassembly and ensuring promoter . Mediator influences modifications, notably promoting H3K27 through its recruitment of p300/CBP HATs, which correlates with increased accessibility and . This mark reduces affinity for DNA, further aiding remodeling by complexes. For example, MED1-dependent recruitment of HATs leads to elevated H3K27ac levels at active promoters, as observed in lipogenic where MED1 scaffolds p300 for targeted . Recent insights from 2021-2024 studies highlight Mediator- interfaces: cryo-EM structures show Mediator's modular head and middle domains interfacing with DNA, while functional assays demonstrate that Mediator-RSC contacts via MED17 and RSC8 subunits fine-tune spacing. Perturbation of subunits reveals quantitative impacts on accessibility. In , mutations in MED17 (e.g., med17-140) disrupt RSC cooperation, resulting in a 2-fold increase in occupancy within promoter NDRs and a reduction in +1 signal as measured by , alongside narrower NDR widths (314 bp for RSC-unique peaks versus 427 bp for Mediator-RSC shared peaks). In mammalian systems, depletion of MED14 causes only modest changes in accessibility at target promoters despite transcriptional downregulation, indicating Mediator's primary role in stabilizing open states rather than initiating broad accessibility shifts. Similarly, MED1 knockout in adipocytes shows no significant alteration in peaks or H3K27ac at lipogenic promoters, underscoring its selective influence on dynamics over global remodeling. These findings emphasize Mediator's nuanced control of local to support transcription.

Enhancer-Promoter Looping

The Mediator complex plays a crucial role in facilitating long-range chromatin interactions by bridging enhancers and promoters, often within phase-separated nuclear condensates that concentrate transcriptional machinery. These condensates, formed by coactivators including Mediator subunits like MED1, enable efficient enhancer-promoter contacts at super-enhancers, where high densities of transcription factors and Mediator promote liquid-liquid phase separation (LLPS) to stabilize looping hubs. Mediator also cooperates with cohesin in loop extrusion processes, stabilizing cohesin occupancy at enhancers to extrude DNA loops that bring distal regulatory elements into proximity with target promoters, thereby enhancing transcriptional activation. Depletion of , such as through rapid degradation of the core subunit MED14, significantly impairs these interactions, reducing enhancer-promoter contact frequencies by approximately 34% across multiple loci and leading to a profound decrease in associated , often by over sevenfold. This effect is particularly evident in high-resolution conformation capture assays like Micro-Capture-C (MCC), which reveal selective disruptions in intra-topologically associating domain (TAD) loops without altering overall TAD boundaries, underscoring 's specific architectural function in looping dynamics. Such studies, conducted in cell lines, demonstrate that 's absence not only diminishes loop stability but also correlates with reduced binding at enhancers, further linking to extrusion-based mechanisms. The tail module of Mediator is pivotal in this process, as it directly engages DNA-bound transcription factors at enhancers, facilitating initial recruitment and subsequent looping to promoters via interactions with the head and middle modules. Structural analyses indicate that the tail module, with subunits such as MED1, MED15, and MED25 forming flexible extensions via intrinsically disordered regions that interact with transcription factors at enhancers, and MED14 providing extensive structural connectivity spanning over 350 Å across the complex, enables the complex to facilitate enhancer-promoter contacts. In the context of super-enhancer architecture, integrates into multi-valent hubs that amplify looping efficiency, as evidenced by and data showing ~22% reduced internal interactions within super-enhancers like those regulating MTAP and HMGA2 upon Mediator depletion. These techniques, applied from 2020 to 2025, highlight how sustains promoter contacts in dense regulatory clusters, with Capture-C interpretations revealing subtle shifts in loop strengths that escape detection in lower-resolution , emphasizing its role in fine-tuning super-enhancer-driven gene regulation.

Regulation and Interactions

Signal Transduction Integration

The Mediator complex serves as a central hub for integrating extracellular signals into gene expression programs by bridging signaling pathways with the transcriptional machinery. Through dynamic conformational changes and subunit-specific interactions, it transduces inputs from diverse pathways, such as MAPK/ERK and ligand-activated receptors, to modulate (Pol II) activity at enhancers and promoters. This integration enables context-dependent transcriptional responses, ensuring precise regulation of cellular processes like proliferation and differentiation. A key mechanism of signal integration involves of Mediator subunits by , particularly within the CDK8 kinase module (MKM), in response to MAPK/ERK signaling. For instance, ERK directly phosphorylates MED14 at serine 986, promoting Mediator recruitment to immediate-early promoters and facilitating rapid transcriptional activation during stimulation. Similarly, the MKM, comprising CDK8 (or CDK19), cyclin C, MED12, and MED13, phosphorylates transcription factors like in MAPK/ERK-activated contexts, enhancing their ability to engage Mediator and drive interferon-responsive genes. These events often induce MKM dissociation from the core Mediator, transitioning it from a repressive to an activating state. Ligand-dependent recruitment exemplifies another integration mode, where nuclear receptors bind the Mediator tail module upon hormone activation. Subunits like MED1, containing nuclear receptor boxes (LXXLL motifs), interact with the activation function-2 (AF2) domain of ligand-bound receptors such as estrogen receptor-α (ERα) or peroxisome proliferator-activated receptor γ (PPARγ), recruiting to target enhancers. This binding induces tail module conformational shifts, stabilizing -Pol II interactions and promoting enhancer-promoter looping for efficient transcription. In hormone signaling, such as thyroid hormone or pathways, this recruitment is context-specific, varying by cell type and coactivator availability to fine-tune gene sets involved in or stress responses. Recent structural and functional studies highlight Mediator's role as a versatile signal hub, with its modular architecture allowing by incoming signals. A 2022 review emphasizes how intrinsic disorder in tail and head modules enables rapid conformational dynamics, integrating inputs from multiple pathways without fixed binding sites. For example, in the Wnt pathway, β-catenin binds MED12 in the MKM, inducing dissociation and activating Wnt target genes like c-Myc by relieving Pol II pausing. Likewise, Notch signaling modulates Mediator conformation via MKM phosphorylation of Notch intracellular domain (NICD), facilitating NICD-Mastermind complexes to recruit Mediator and sustain oscillatory in developmental contexts. Recent work as of 2025 has also implicated MED14 in GLP-1 agonist signaling for beta-cell gene regulation. These examples underscore Mediator's capacity to decode signal-specific cues into tailored transcriptional outputs.

Protein-Protein Interactions

The Mediator complex engages in dynamic protein-protein interactions with various coactivators to facilitate . Notably, Mediator synergizes with the histone acetyltransferases p300 and CBP, where p300 recruits Mediator to through interactions mediated by steroid receptor coactivators (SRCs) such as SRC-1. This association enhances the recruitment of additional coactivators to promoter regions, as demonstrated in alpha-dependent contexts. Mediator also interacts with other coactivators like PGC-1α, where binding induces structural rearrangements that stabilize the complex. Mediator binds directly to sequence-specific transcription factors (TFs) through its tail module, which recognizes activation domains (ADs). The viral TF VP16 interacts with Mediator subunits such as MED25 (ARC92), serving as a functional target for VP16-mediated activation. Similarly, the p65 subunit of docks onto Mediator via its transactivation domain, facilitating inflammatory gene regulation. These TF-Mediator contacts are often "fuzzy" in nature, allowing flexible binding to diverse ADs. Recent approaches have generated genome-wide interaction maps of , revealing extensive binding networks. Affinity purification-mass spectrometry (AP-MS) and proximity-dependent (BioID) studies from 2020–2024 identified numerous high-confidence interactions between and TFs, with common partners including nuclear receptors and signaling TFs like Elk-1. These maps highlight 's role as a hub, with tail subunits showing the highest connectivity to sequence-specific regulators. TF binding to induces allosteric effects that propagate conformational changes across the complex. For example, phosphorylation-dependent binding of Elk-1 to MED23 triggers dynamic rearrangements in the Mediator head module, altering its interface with . Such allostery enhances Mediator's responsiveness, as seen with VP16 binding to MED15, which stabilizes fuzzy interactions and modulates subunit positioning. Beyond transcription, Mediator maintains non-transcriptional partnerships, including links to the for subunit turnover. In and mammalian systems, certain Mediator subunits interact with the proteasome regulatory particle, facilitating ubiquitin-proteasome-mediated degradation to regulate complex integrity.

Specific Subunits and Regulation

MED1 Functions

MED1, also known as TRAP220 or PPAR-binding protein (PBP), serves as a key coactivator subunit of the Mediator complex, particularly in facilitating ligand-dependent interactions with nuclear receptors such as the (TR) and receptor (RAR).80586-3.pdf) It contains multiple (NR)-interacting domains (NIDs), including LXXLL motifs, that enable direct binding to the ligand-binding domains of these receptors upon agonist activation, thereby bridging nuclear receptors to the core Mediator complex to promote target transcription. This coactivation is essential for hormone-responsive , with MED1 recruiting Mediator to enhancers in a receptor-specific manner.80586-3.pdf) MED1 integrates into the middle module of complex, where it occupies a peripheral position that allows flexible interactions with activators. Its association with is regulated by , primarily at residues 1032 and 1457 by extracellular signal-regulated (ERK), which enhances MED1's binding affinity and stabilizes its incorporation into the complex during transcriptional activation. Additional by cyclin-dependent 7 (CDK7) further modulates MED1's role in promoter recruitment. Recent structural studies, including cryo-EM analyses of the human complex, have elucidated MED1's positioning within the middle module, revealing its extended, intrinsically disordered regions (IDRs) that facilitate dynamic conformational changes upon activator binding. These structures show MED1 extending from the core middle module toward the surface, enabling interactions with nuclear receptors while maintaining 's overall modular architecture. MED1 exhibits tissue-specific expression patterns, with high levels in metabolically active tissues such as liver, adipose, and muscle, reflecting its roles in hormone-regulated processes. In mouse models, global MED1 knockout is embryonic lethal, but conditional knockouts reveal diverse phenotypes: in adipose tissue, MED1 ablation disrupts brown and white adipocyte differentiation, leading to lipodystrophy and impaired thermogenesis; muscle-specific deletion increases mitochondrial density and shifts fiber type toward slow-twitch, enhancing insulin sensitivity; and hepatocyte-specific loss impairs regeneration and energy homeostasis. In mediator-dependent gene activation, MED1 is crucial for integrating nuclear receptor signals into transcriptional outputs, particularly in liver metabolism, where it mediates peroxisome proliferator-activated receptor (PPAR)-driven lipid homeostasis and gluconeogenesis. For instance, MED1 facilitates PPARγ and PPARα activation of lipogenic and oxidative genes, and its deficiency attenuates high-fat diet-induced steatosis while preserving adaptive responses to fasting. This underscores MED1's role in fine-tuning metabolic gene networks through Mediator.

MicroRNA and Developmental Regulation

MicroRNAs (miRNAs) play a critical role in of the complex, particularly targeting subunit MED1 to modulate its expression during development and in pathological contexts such as cancer. For instance, , a muscle-specific miRNA essential for cardiac and differentiation, directly suppresses MED1 by binding to its 3' , thereby inhibiting proliferation in cells and influencing in developmental lineages. This suppression highlights miR-1's dual role in fine-tuning activity to prevent aberrant cell growth while supporting tissue-specific . Similarly, miR-146a targets MED1 to regulate hepatic lipid and glucose metabolism, demonstrating miRNA-mediated control over in organ development and . In mouse embryonic stem cells (ESCs), the Mediator complex is indispensable for differentiation, coordinating networks that drive lineage commitment. Disruption of subunits, such as Med23, enhances neural differentiation by altering BMP signaling pathways, underscoring Mediator's role in maintaining pluripotency and facilitating exit from the state. Likewise, the cyclin-dependent kinase module (CKM) of interacts with Polycomb repressive complexes to repress developmental genes in ESCs, integrating epigenetic silencing with transcriptional activation during embryogenesis; loss of CKM components leads to derepression and impaired lineage specification. Tissue-specific effects of Mediator are evident in mouse models, where conditional knockouts reveal essential functions in organogenesis. In the liver, MED1 ablation prevents fatty liver development under high-fat diets by disrupting lipid metabolism gene expression, while maintaining embryonic viability through tissue-specific targeting. Cardiac-specific deletion of Med1 induces early lethality, remodeling, and hypertrophy due to failed integration of metabolic and contractile gene programs, emphasizing Mediator's coordination of heart development. Conditional knockouts of subunits consistently demonstrate developmental when globally disrupted, necessitating tissue-specific approaches to study embryogenesis. For example, Med28 deficiency causes peri-implantation , while Med1 deletion results in mid-gestational failure with multi-organ defects, highlighting the complex's indispensable role in early embryo survival. These models reveal how bridges signaling and epigenetic regulators, such as modifiers, to orchestrate waves during embryogenesis from 2020-2023 studies.

Disease and Evolutionary Aspects

Associations with Human Diseases

Mutations in subunits of the Mediator complex have been implicated in various congenital disorders, particularly those affecting neurodevelopment and cardiac function. For instance, heterozygous loss-of-function mutations or haploinsufficiency in MED13L are associated with MED13L syndrome, characterized by intellectual disability, developmental delay, hypotonia, and facial dysmorphisms, as evidenced by genetic studies in affected families and patient cohorts. These mutations disrupt Mediator's role in transcriptional regulation during embryogenesis, leading to broad phenotypic variability including behavioral abnormalities. Similarly, missense mutations in MED12, such as those in the LCE motif, contribute to X-linked intellectual disability syndromes like FG syndrome and Ohdo syndrome, with functional evidence from patient-derived fibroblasts showing impaired Wnt signaling. In , alterations in subunits are frequently observed, with MED12 hotspot (e.g., c.131G>A) driving approximately 70% of uterine leiomyomas by activating β-catenin-dependent transcription and promoting tumor growth. These are mutually exclusive with HMGA2 rearrangements and correlate with smaller tumor size but higher recurrence risk, as confirmed in large genomic profiling studies of over 1,000 leiomyomas. Overexpression or amplification of MED1 occurs in about 50% of and cancers, enhancing and activity to support proliferation, while CDK8 amplification in sustains oncogenic Wnt/β-catenin signaling. Genome-wide association studies (GWAS) have also linked variants near MED23 to increased risk, highlighting Mediator's broader role in susceptibility loci. Mediator dysregulation contributes to metabolic pathologies, notably through MED1, which mediates nuclear receptor signaling in glucose and lipid homeostasis. Muscle-specific MED1 knockout in mice leads to enhanced energy expenditure and protection against diet-induced obesity and insulin resistance, suggesting MED1 as a potential therapeutic target for type 2 diabetes; human studies show MED1 polymorphisms associated with altered hepatic lipid metabolism and glycemic control. In liver, miR-146a-mediated suppression of MED1 improves mitochondrial function and reduces steatosis, linking Mediator to non-alcoholic fatty liver disease progression in diabetic patients. Therapeutic strategies targeting , particularly the kinase module, are advancing in . Selective CDK8/CDK19 inhibitors like SEL120 (RVU120) are in phase I/II clinical trials (initiated 2020, ongoing as of 2025) for , myelofibrosis, and solid tumors, demonstrating efficacy in Phase II studies including suppression of /SOCS3 signaling and tumor growth with manageable toxicity. As of 2025, Phase II data from the POTAMI-61 trial show promising activity in myelofibrosis, both as monotherapy and in combination with . Similarly, BCD-115 is under investigation in early-phase trials for advanced and TSN084 for advanced malignant tumors, capitalizing on CDK8's role in regulation within the . Patient studies correlate CDK8 expression levels with poor in colorectal and cancers, supporting these inhibitors' potential.

Variations Across Species

The Mediator complex exhibits significant variations across species, reflecting evolutionary adaptations to diverse transcriptional needs. In the budding yeast , the complex consists of 25 subunits organized into head, middle, tail, and a dissociable (CKM) modules, with the core (head and middle) providing essential scaffolding for interaction, while the tail module serves as a regulatory interface for activators. The CKM, comprising Cdk8, cyclin C, Med12, and Med13, associates reversibly with the core and modulates transcription elongation, but its absence in certain genetic strains or conditions highlights its non-essential, regulatory role in yeast compared to more integrated functions in higher eukaryotes. In plants, such as , the Mediator is larger and more specialized, comprising approximately 37 subunits, including unique tail module components like MED32 and MED33 that are absent in and metazoans. These plant-specific subunits enable tailored responses to environmental cues, with MED25 (also known as PFT1) playing a central role in signaling and MED16 regulating abiotic stresses like and . Additionally, plant Mediator shows enhanced involvement in developmental and stress-responsive pathways, such as via MED8, distinguishing it from the more general transcriptional roles in . Evolutionarily, the core modules (head and middle) of are highly conserved across eukaryotes, with over 80% of subunits sharing sequence similarity from fungi to plants and metazoans, underscoring their fundamental role in basal transcription machinery. In contrast, the tail module displays marked divergence, with featuring a simpler set of 3–5 subunits (e.g., Med2, Med3, Med5, Med15, Med16) that loosely tether activators, while metazoan tails expand to 6–9 subunits, incorporating species-specific elements for complex signaling integration. This divergence likely arose to accommodate organism-specific regulatory demands, as evidenced by showing tail subunits evolving faster than core ones. Recent structural studies from 2020–2024, using cryo-EM and modeling, reveal both conservation and differences between fungal () and metazoan (mammalian) Mediators. The head and middle modules maintain similar architectures, with MED14 acting as a conserved scaffold, but mammalian versions exhibit conformational flexibility at inter-module interfaces absent in rigid structures. Fungal tails are compact and minimally interactive with the core, whereas metazoan tails form extensive contacts via elongated MED14 extensions, stabilizing the complex for diverse activator binding; these insights from high-resolution models (e.g., RMSD < 2 Å for core subunits) highlight adaptive structural .

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC9207880/
  2. https://www.jbc.org/article/S0021-9258(20)30931-5/fulltext
  3. https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.16250
  4. https://www.sciencedirect.com/science/article/pii/S1097276524007342
  5. https://www.science.org/doi/10.1126/science.abg0635
  6. https://www.mdpi.com/2073-4409/14/17/1335
  7. https://www.tandfonline.com/doi/full/10.3109/10409238.2013.840259
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC3531718/
  9. https://www.science.org/doi/10.1126/science.abg3074
  10. https://elifesciences.org/articles/39633
  11. https://www.pnas.org/doi/10.1073/pnas.2220542120
  12. https://www.sciencedirect.com/science/article/pii/S1097276521000423
  13. https://www.nature.com/articles/s41467-021-21601-w
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC7385929/
  15. https://www.nature.com/articles/s41467-020-14849-1
  16. https://www.science.org/doi/10.1126/science.aar4199
  17. https://academic.oup.com/nar/article/47/22/11481/5625531
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3630880/
  19. https://doi.org/10.1016/j.molcel.2025.05.006
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3207035/
  21. https://www.cell.com/cell-reports/fulltext/S2211-1247(23)00476-X
  22. https://www.science.org/doi/10.1126/science.abn8131
  23. https://journals.physiology.org/doi/10.1152/ajpheart.00580.2018
  24. https://www.cell.com/cell/pdf/S0092-8674%2825%2901178-X.pdf
  25. https://genesdev.cshlp.org/content/35/9-10/713.full
  26. https://www.science.org/doi/10.1126/science.aar3958
  27. https://www.nature.com/articles/s12276-024-01233-y
  28. https://www.nature.com/articles/s41594-023-01027-2
  29. https://www.science.org/doi/10.1126/sciadv.adl4893
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC3217725/
  31. https://academic.oup.com/nar/article/41/22/10241/2438897
  32. https://www.cell.com/trends/biochemical-sciences/fulltext/S0968-0004(22)00005-6
  33. https://pubmed.ncbi.nlm.nih.gov/16565090/
  34. https://elifesciences.org/articles/92083
  35. https://www.biorxiv.org/content/10.1101/2025.06.17.660196v1
  36. https://pubmed.ncbi.nlm.nih.gov/12727881/
  37. https://pubmed.ncbi.nlm.nih.gov/12482985/
  38. https://www.nature.com/articles/s41392-023-01651-w
  39. https://pubmed.ncbi.nlm.nih.gov/14983011/
  40. https://pubmed.ncbi.nlm.nih.gov/10235267/
  41. https://www.nature.com/articles/s41467-021-22441-4
  42. https://www.nature.com/articles/s41467-022-28341-5
  43. https://www.nature.com/articles/s41467-019-10502-8
  44. https://www.nature.com/articles/s41467-025-59014-8
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4963239/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC7641746/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC2423130/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC4093800/
  49. https://www.biorxiv.org/content/10.1101/2024.03.18.585606v1.full-text
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC8091968/
  51. https://www.pnas.org/doi/10.1073/pnas.1005626107
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3784705/
  53. https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.24155
  54. https://www.spandidos-publications.com/10.3892/or.2014.3274
  55. https://www.eymj.org/DownloadSupplMaterial.php?id=10.3349/ymj.2020.61.9.780&fn=ymj-61-780-s002.pdf
  56. https://journals.biologists.com/dev/article/142/3/465/47157/Mediator-Med23-deficiency-enhances-neural
  57. https://www.nature.com/articles/s41594-022-00840-5
  58. https://link.springer.com/article/10.1007/s41048-016-0031-6
  59. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0160755
  60. https://pmc.ncbi.nlm.nih.gov/articles/PMC10252979/
  61. https://www.ncbi.nlm.nih.gov/books/NBK613517/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC4100472/
  63. https://www.nature.com/articles/s41467-023-39684-y
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC5765725/
  65. https://www.ebi.ac.uk/gwas/search?query=MED23
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC2890439/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC6984781/
  68. https://synapse.patsnap.com/article/what-cdk8-inhibitors-are-in-clinical-trials-currently
  69. https://ryvu.com/press-release/ryvu-therapeutics-presents-data-on-rvu120-at-the-european-hematology-association-congress-2025
  70. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1386929/full
  71. https://clinicaltrials.gov/study/NCT03065010
  72. https://clinicaltrials.gov/study/NCT06386705
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC1456402/
  74. https://doi.org/10.1016/j.molcel.2007.05.007
  75. https://doi.org/10.1038/s41598-020-61758-w
  76. https://doi.org/10.1093/nar/gkn349
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC3207015/
  78. https://academic.oup.com/pcp/article/58/1/04/2671014
  79. https://febs.onlinelibrary.wiley.com/doi/10.1111/febs.17225
Add your contribution
Related Hubs
User Avatar
No comments yet.